SI-BONE, Inc. Share Price

Equities

SIBN

US8257041090

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 11/07/2024 BST 5-day change 1st Jan Change
14.73 USD +8.71% Intraday chart for SI-BONE, Inc. +12.96% -29.82%
Sales 2024 * 165M 12.75B Sales 2025 * 195M 15.01B Capitalization 607M 46.83B
Net income 2024 * -39M -3.01B Net income 2025 * -33M -2.55B EV / Sales 2024 * 3.05 x
Net cash position 2024 * 103M 7.95B Net cash position 2025 * 88.22M 6.81B EV / Sales 2025 * 2.67 x
P/E ratio 2024 *
-15.5 x
P/E ratio 2025 *
-18.8 x
Employees 344
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day+8.71%
1 week+12.96%
Current month+13.92%
1 month+12.10%
3 months-6.12%
6 months-24.62%
Current year-29.82%
More quotes
1 week
12.96
Extreme 12.96
14.86
1 month
11.76
Extreme 11.76
14.86
Current year
11.76
Extreme 11.76
21.64
1 year
11.76
Extreme 11.76
27.86
3 years
11.14
Extreme 11.14
31.54
5 years
7.20
Extreme 7.2
37.21
10 years
7.20
Extreme 7.2
37.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 25/05/15
Founder 69 17/03/08
Director of Finance/CFO 44 18/04/21
Members of the board TitleAgeSince
Founder 69 17/03/08
Director/Board Member 70 31/12/12
Director/Board Member 77 31/12/10
More insiders
Date Price Change Volume
11/07/24 14.73 +8.71% 341,108
10/07/24 13.55 +0.74% 227,715
09/07/24 13.45 -0.30% 282,879
08/07/24 13.49 +3.85% 671,330
05/07/24 12.99 -0.38% 192,874

Delayed Quote Nasdaq, July 11, 2024 at 09:00 pm

More quotes
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.73 USD
Average target price
25.56 USD
Spread / Average Target
+73.49%
Consensus